Correction to: Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2) (Advances in Therapy, (2025), 42, 1, (132-143), 10.1007/s12325-024-02974-y)

Eric Simpson; Pablo Fernández-Peñas; Marjolein de Bruin-Weller; Peter A. Lio; Chia Yu Chu; Khaled Ezzedine; Helena Agell; Marta Casillas; Yuxin Ding; Fan Emily Yang; Evangeline Pierce; Thomas Bieber

doi:10.1007/s12325-024-03010-9

Correction to: Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2) (Advances in Therapy, (2025), 42, 1, (132-143), 10.1007/s12325-024-02974-y)

Eric Simpson^*, Pablo Fernández-Peñas, Marjolein de Bruin-Weller, Peter A. Lio, Chia Yu Chu, Khaled Ezzedine, Helena Agell, Marta Casillas, Yuxin Ding, Fan Emily Yang, Evangeline Pierce, Thomas Bieber

^*Corresponding author for this work

Dermatology

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The legend for Fig. 4 has published as “Skin improvements in two patients treated with lebrikizumab. a Antecubital fossa and b hand at baseline and at 2, 8, and 16 weeks of lebrikizumab treatment. Corresponding values and percent improvements from baseline in EASI, Pruritus NRS, POEM, and DLQI are listed below each photo.

Original language	English (US)
Pages (from-to)	144-145
Number of pages	2
Journal	Advances in Therapy
Volume	42
Issue number	1
DOIs	https://doi.org/10.1007/s12325-024-03010-9
State	Published - Jan 2025

ASJC Scopus subject areas

Pharmacology (medical)

Access to Document

10.1007/s12325-024-03010-9

Fingerprint

Dive into the research topics of 'Correction to: Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2) (Advances in Therapy, (2025), 42, 1, (132-143), 10.1007/s12325-024-02974-y)'. Together they form a unique fingerprint.

Cite this

Simpson, E., Fernández-Peñas, P., de Bruin-Weller, M., Lio, P. A., Chu, C. Y., Ezzedine, K., Agell, H., Casillas, M., Ding, Y., Yang, F. E., Pierce, E., & Bieber, T. (2025). Correction to: Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2) (Advances in Therapy, (2025), 42, 1, (132-143), 10.1007/s12325-024-02974-y). Advances in Therapy, 42(1), 144-145. https://doi.org/10.1007/s12325-024-03010-9

Simpson, Eric ; Fernández-Peñas, Pablo ; de Bruin-Weller, Marjolein et al. / Correction to : Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2) (Advances in Therapy, (2025), 42, 1, (132-143), 10.1007/s12325-024-02974-y). In: Advances in Therapy. 2025 ; Vol. 42, No. 1. pp. 144-145.

@article{b1276270280a4cb4a05df5fceb1582dd,

title = "Correction to: Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2) (Advances in Therapy, (2025), 42, 1, (132-143), 10.1007/s12325-024-02974-y)",

abstract = "The legend for Fig. 4 has published as “Skin improvements in two patients treated with lebrikizumab. a Antecubital fossa and b hand at baseline and at 2, 8, and 16 weeks of lebrikizumab treatment. Corresponding values and percent improvements from baseline in EASI, Pruritus NRS, POEM, and DLQI are listed below each photo.",

author = "Eric Simpson and Pablo Fern{\'a}ndez-Pe{\~n}as and {de Bruin-Weller}, Marjolein and Lio, {Peter A.} and Chu, {Chia Yu} and Khaled Ezzedine and Helena Agell and Marta Casillas and Yuxin Ding and Yang, {Fan Emily} and Evangeline Pierce and Thomas Bieber",

note = "Publisher Copyright: {\textcopyright} Springer Healthcare Ltd., part of Springer Nature 2024.",

year = "2025",

month = jan,

doi = "10.1007/s12325-024-03010-9",

language = "English (US)",

volume = "42",

pages = "144--145",

journal = "Advances in Therapy",

issn = "0741-238X",

publisher = "Adis",

number = "1",

}

Simpson, E, Fernández-Peñas, P, de Bruin-Weller, M, Lio, PA, Chu, CY, Ezzedine, K, Agell, H, Casillas, M, Ding, Y, Yang, FE, Pierce, E & Bieber, T 2025, 'Correction to: Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2) (Advances in Therapy, (2025), 42, 1, (132-143), 10.1007/s12325-024-02974-y)', Advances in Therapy, vol. 42, no. 1, pp. 144-145. https://doi.org/10.1007/s12325-024-03010-9

Correction to: Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2) (Advances in Therapy, (2025), 42, 1, (132-143), 10.1007/s12325-024-02974-y). / Simpson, Eric; Fernández-Peñas, Pablo; de Bruin-Weller, Marjolein et al.
In: Advances in Therapy, Vol. 42, No. 1, 01.2025, p. 144-145.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - Correction to

T2 - Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2) (Advances in Therapy, (2025), 42, 1, (132-143), 10.1007/s12325-024-02974-y)

AU - Simpson, Eric

AU - Fernández-Peñas, Pablo

AU - de Bruin-Weller, Marjolein

AU - Lio, Peter A.

AU - Chu, Chia Yu

AU - Ezzedine, Khaled

AU - Agell, Helena

AU - Casillas, Marta

AU - Ding, Yuxin

AU - Yang, Fan Emily

AU - Pierce, Evangeline

AU - Bieber, Thomas

PY - 2025/1

Y1 - 2025/1

N2 - The legend for Fig. 4 has published as “Skin improvements in two patients treated with lebrikizumab. a Antecubital fossa and b hand at baseline and at 2, 8, and 16 weeks of lebrikizumab treatment. Corresponding values and percent improvements from baseline in EASI, Pruritus NRS, POEM, and DLQI are listed below each photo.

AB - The legend for Fig. 4 has published as “Skin improvements in two patients treated with lebrikizumab. a Antecubital fossa and b hand at baseline and at 2, 8, and 16 weeks of lebrikizumab treatment. Corresponding values and percent improvements from baseline in EASI, Pruritus NRS, POEM, and DLQI are listed below each photo.

UR - http://www.scopus.com/inward/record.url?scp=85216881862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85216881862&partnerID=8YFLogxK

U2 - 10.1007/s12325-024-03010-9

DO - 10.1007/s12325-024-03010-9

M3 - Comment/debate

C2 - 39636571

AN - SCOPUS:85216881862

SN - 0741-238X

VL - 42

SP - 144

EP - 145

JO - Advances in Therapy

JF - Advances in Therapy

IS - 1

ER -

Simpson E, Fernández-Peñas P, de Bruin-Weller M, Lio PA, Chu CY, Ezzedine K et al. Correction to: Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2) (Advances in Therapy, (2025), 42, 1, (132-143), 10.1007/s12325-024-02974-y). Advances in Therapy. 2025 Jan;42(1):144-145. doi: 10.1007/s12325-024-03010-9

Correction to: Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2) (Advances in Therapy, (2025), 42, 1, (132-143), 10.1007/s12325-024-02974-y)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this